Search Results
neoplasms. Eur J Haematol. 2015; 95: 270–279. 3 Tefferi A. Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management. Am J
. Med., 2013, 369 (25), 2379–2390. 3 Moulard, O., Mehta, J., Fryzek, J., et al.: Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European
constitutive signalling causes polycythaemia vera. Nature, 2005, 434 (7037), 1144–1148. Kralovics, R., Passamonti, F., Buser, A. S., et al.: A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J
, A., Barbui, T.: Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. Am. J. Hematol., 2015, 90 (2), 162–173. 8
–2720. Marchetti, M., Castoldi, E., Spronk, H. M., et al.: Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. Blood, 2008, 112 (10), 4061–4068. Panova
ONE 2020; 15: e0226879. 25 Gisslinger H, Klade C, Georgiev P, et al. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera
myelofibrosis, essential thrombocythaemia and polycythaemia vera in the European Union. Eur J Haematol. 2014; 92: 289–297. 37 Jakó J, Szerafin L
clinical presentation, BCS can be classified as fulminant, acute, subacute, or chronic [ 2 ]. The most common underlying disorders in patients with BCS are hematologic abnormalities, such as polycythemia vera and essential thrombocytosis [ 3 ]. In Western
